Herceptin (HER2-Positive Breast Cancer) – Forecast and Market Analysis to 2023

Pages: 58 Published: September 01, 2014 Report Code: GDHC463DFR

GlobalData has released its new PharmaPoint Drug Evaluation report, “Herceptin (HER2-Positive Breast Cancer) – Forecast and Market Analysis to 2023”. HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the HER2-positive breast cancer market, with coverage of multiple settings of the disease including neoadjuvant, adjuvant, first-, second-, third-, and fourth-line metastatic. Roche/Genentech’s Herceptin (trastuzumab), first approved in the US in 1998, and in the EU in 2000, is the gold-standard treatment for HER2-positive breast cancer, and is prescribed both for patients with early-stage and metastatic disease. Herceptin is an intravenously-administered mAb that targets the HER2 receptor, blocking the downstream signaling pathways that support tumor cell survival (Genentech, 2013).

Scope

Overview of HER2-Positive Breast Cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

Detailed information on Herceptin including product description, safety and efficacy profiles as well as a SWOT analysis.

Sales forecast for Herceptin for the top eight countries from 2013 to 2023.

Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and China.

Reasons to Buy

Understand and capitalize by identifying products that are most likely to ensure a robust return

Stay ahead of the competition by understanding the changing competitive landscape for HER2-Positive Breast Cancer

Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

Make more informed business decisions from insightful and in-depth analysis of Herceptin performance

Obtain sales forecast for Herceptin from 2013-2023 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and China)

Table of Contents

1Table of Contents

1.1List of Tables

1.2List of Figures

2Introduction

2.1Catalyst

2.2Related Reports

2.3Upcoming Related Reports

3Disease Overview

3.1Etiology and Pathophysiology

3.1.1Etiology

3.1.2Pathophysiology

3.2Basic Breast Anatomy

3.3Breast Cancer Staging

3.4Prognosis

3.5Quality of Life

3.6Symptoms

4Disease Management

4.1Treatment Overview

4.1.1Treatment of Early-Stage Breast Cancer (Stage 0 to Stage IB)

4.1.2Treatment of Locally-Advanced and Regional Breast Cancer (Stage IB to IIIA)

4.1.3Treatment of Metastatic HER2-Positive Breast Cancer (Stage IV)

5Competitive Assessment

5.1Overview

6Herceptin (trastuzumab)

6.1Overview

6.2Efficacy

6.3Safety

6.4SWOT Analysis

6.5Forecast

7Appendix

7.1Bibliography

7.2Abbreviations

7.3Methodology

7.4Forecasting Methodology

7.4.1Diagnosed HER2-Positive Breast Cancer Patients

7.4.2Percent Drug-Treated Patients

7.4.3General Pricing Assumptions

7.4.4Individual Drug Assumptions

7.5Primary Research – KOLs Interviewed for this Report

7.6Primary Research – Prescriber Survey

7.7About the Authors

7.7.1Analyst

7.7.2Therapy Area Director

7.7.3Global Head of Healthcare

7.8About GlobalData

7.9Disclaimer

List of Tables

Table 1: AJCC Stage Definitions for Breast Cancer

Table 2: Prognosis for Breast Cancer in the US

Table 3: Treatment Guidelines for HER2-Positive Breast Cancer

Table 4: Product Profile – Herceptin

Table 5: Clinical Studies for Herceptin in the Adjuvant Setting

Table 6: Herceptin SWOT Analysis, 2013

Table 7: Global Sales Forecast ($m) for Herceptin, 2013–2023

Table 8: HER2-Positive Breast Cancer Incidence, 2013–2023

Table 9: Average Body Weight and Surface Area Across the 8MM

Table 10: Average Annual Cost of Therapy ($) – Herceptin, Adjuvant

Table 11: Average Annual Cost of Therapy ($) – Subcutaneous Herceptin, Adjuvant

Table 12: Physicians Surveyed by Country

List of Figures

Figure 1: Basic Breast Anatomy, Including Key Lymph Nodes

$3,495

Can be used by individual purchaser only

$10,485

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about our multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

Every customer’s requirement is unique. We understand that and can customize the report basis your exact research requirements pertaining to market insights, innovation insights, strategy and planning, and competitive intelligence. You can also avail the option of purchasing stand-alone sections of the report or request for a country specific report.

Still undecided about purchasing this report?

Testimonial

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods